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Abstract
Macrophages constitute a major component of innate immunity and play an essential role in defense mechanisms against
external aggressions and in inflammatory responses. Chemerin, a chemoattractant protein, is generated in inflammatory
conditions, and recruits cells expressing the G protein-coupled receptor ChemR23, including macrophages. Chemerin was
initially expected to behave as a pro-inflammatory agent. However, recent data described more complex activities that are
either pro- or anti-inflammatory, according to the disease model investigated. In the present study, peritoneal macrophages
were generated from WT or ChemR23
2/2 mice, stimulated with lipopolyssaccharide in combination or not with IFN-c and
the production of pro- (TNF-a, IL-1b and IL-6) and anti-inflammatory (IL-10) cytokines was evaluated using qRT-PCR and
ELISA. Human macrophages generated from peripheral blood monocytes were also tested in parallel. Peritoneal
macrophages from WT mice, recruited by thioglycolate or polyacrylamide beads, functionally expressed ChemR23, as
assessed by flow cytometry, binding and chemotaxis assays. However, chemerin had no effect on the strong upregulation of
cytokine release by these cells upon stimulation by LPS or LPS/IFN-c, whatever the concentration tested. Similar data were
obtained with human macrophages. In conclusion, our results rule out the direct anti-inflammatory effect of chemerin on
macrophages ex vivo, described previously in the literature, despite the expression of a functional ChemR23 receptor in
these cells.
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Introduction
As humans are continuously exposed to miscellaneous injuries,
inflammation occurs frequently as a result of the activation of
protective systems. Higher vertebrates have developed two highly
interconnected systems of protection: the innate and adaptive
immune systems, for the purpose of eliminating pathogenic insults,
removing damaged tissues, and restoring tissue homeostasis [1].
Macrophages constitute a major component of innate immunity
and play an essential role in defense mechanisms against external
aggressions such as infectious diseases. These properties are
mediated in part by their ability to synthesize cytokines and
chemokines, which in turn modulate and recruit other leukocyte
subsets, linking innate and adaptive immune responses [2].
Moreover, macrophages are also important players in the
resolution phase of inflammation, a process considered as passive
till recently. Indeed, as a result of their phagocytic properties,
macrophages mediate the uptake and clearance of apoptotic cells,
necrotic cell debris and wounded tissue components [3].
Chemoattractant agents play a crucial role in the initiation of
immune responses, by regulating the traffic and function of
leukocyte populations. Their receptors are therefore considered as
potential targets for the development of new therapeutic agents,
particularly in the fields of cancer and chronic inflammatory
diseases. Chemerin is a small protein of 16 kDa isolated and
identified from human inflammatory fluids as the natural ligand of
the previously orphan G protein-coupled receptor ChemR23 (also
termed CMKLR-1), and acting as a chemoattractant agent for
leukocytes expressing this receptor [4]. ChemR23 is expressed by
myeloid (mDC) and plasmacytoid dendritic cells (pDC), macro-
phages and NK cells [4–9]. Two additional receptors have been
reported to bind chemerin with high affinity, GPR1 [10] and
CCLR2 [11,12], but the biological significance of these receptors
in the activities of chemerin is still not known. In contrast,
chemerin exerts, through ChemR23, potent chemoattractant
properties on leukocyte populations at subnanomolar concentra-
tions [7,13,14]. Chemerin is synthesized as an inactive precursor,
called prochemerin, present at high concentration in plasma.
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agonist by proteolytic removal of a carboxy terminal hexa- or
heptapeptide. This maturation step is mediated by neutrophil-
derived serine proteases (elastase and cathepsin G) and serine
proteases of the coagulation and fibrinolytic cascades, released or
activated as a result of tissue injury, inflammation or infection
[13,15,16]. Chemerin was also described as an adipokine, playing
various roles in the regulation of adipocyte differentiation and the
metabolism of lipids and carbohydrates [17–19].
In addition to its chemoattractant functions, chemerin was
proposed to display anti-inflammatory properties on mouse
peritoneal macrophages at low picomolar concentrations, damp-
ening the production of pro-inflammatory cytokines and enhanc-
ing the production of anti-inflammatory cytokines by these cells
[20]. These observations might have explained our own in vivo
results showing an anti-inflammatory role of chemerin in a LPS-
induced acute lung injury model [7] and in a model of acute viral
pneumonia [8]. We therefore studied ex vivo the anti-inflammatory
properties of chemerin within a large range of concentrations on
mouse and human macrophages, but failed to confirm any effects
of chemerin on the production of pro- and anti-inflammatory
cytokines by these cells following their activation by LPS and/or
IFN-c.
Methods
Ethics statement
The experiments using human samples and animals were
carried out in strict accordance with the national, European (EU
Directives 86/609/EEC) and international guidelines in use at the
Universite ´ Libre de Bruxelles and in accordance with the Helsinki
Declaration. All procedures were reviewed and approved by the
local ethic committee (Commission d’Ethique du Bien-Etre
Animal, CEBEA) of the Universite ´ Libre de Bruxelles (Permit
Number: 222N and 341N). All efforts were made to minimize
suffering. Written informed consent was obtained from all
participants.
Animals
Eight to 12-week-old male C57BL/6 mice (Harlan Netherlands)
were used throughout the study. ChemR23 knockout
(ChemR23
2/2) mice were obtained from Deltagen and back-
crossed for more than 10 generations onto the C57BL/6
background in a specific pathogen-free environment. Heterozy-
gotes (ChemR23
+/2) were then intercrossed to generate F2
ChemR23
2/2 mice and their wild-type (WT) controls.
Mouse peritoneal macrophage preparations
Mouse peritoneal macrophages were collected by using two
different protocols. In a first set of experiments, macrophages were
harvested 4 days following i.p. injection of a 2% thioglycolate
broth. Following sacrifice, the exudate was collected by washing
the peritoneal cavity with 265 ml of cold PBS (Invitrogen, Gibco,
Gent, Belgium). Harvested cells were pooled, centrifuged, washed
with PBS (Invitrogen) and resuspended in RPMI 1640 medium
(Invitrogen) supplemented with 100 U/ml penicillin (Invitrogen),
100 mg/ml streptomycin (Invitrogen) and 10% heat-inactivated
fetal bovine serum (FBS, Invitrogen). Cells were then seeded in 48-
well tissue culture plates (Nunc, 4.10
5 cells in 500 ml) and allowed
to adhere for 1 h at 37uC in a humidified atmosphere containing
5% CO2. Non-adherent cells were removed, and adherent cells
were further used for the macrophage activation assay. The purity
of the adherent macrophage population was evaluated by flow
cytometry (F4-80
+ Gr1
2 cells) to over 90%. In a second set of
experiments, WT and ChemR23
2/2 C57BL/6 mice (5 mice/
group) were injected i.p. with 1 ml of a Bio-Gel P100 poly-
acrylamide bead suspension (2% w/v in PBS, Bio-Rad Labora-
tories, Nazareth-Eke, Belgium), as described by Cash and
colleagues [20]. Four days later, mice were sacrificed and the
exudate was collected as above. Washed harvested cells were
resuspended in Opti-MEM I medium (Gibco) supplemented with
100 U/ml penicillin and 100 mg/ml streptomycin. The collected
cells were either used directly for the chemotaxis assay, binding
assay and flow cytometry analysis, or seeded in 48-well culture
plates (Nunc, 4.10
5 cells in 500 ml), and cultured at 37uCi n
a humidified atmosphere containing 5% CO2. Non-adherent cells
were removed after 2 or 24 hours by extensive washing and
adherent cells were used for the macrophage activation assay and
chemotaxis assay, respectively. The population of adherent cells
was consistently composed of .90% F4-80
+ Gr1
2 macrophages,
as determined by flow cytometry analysis.
Human macrophage preparations
Human macrophages were prepared as previously described
[21]. Briefly, leukocytes were recovered from buffy coats of healthy
donors on a Ficoll (Lymphoprep Axis-Schield) density gradient
and erythrocytes were lysed by ammonium chloride. Monocytes
were purified by positive selection using CD14 microbeads
(Miltenyi Biotec, Leiden, The Netherlands), were resuspended at
the density of 10
6 cells/ml, and seeded in six-well plates (Nunc) in
RPMI 1640 medium (Invitrogen) supplemented with 10% heat-
inactivated FBS (Invitrogen). Macrophages were differentiated
from monocytes in the presence of recombinant human M-CSF
(50 ng/ml, Peprotech, London, UK) for 6 to 11 days. The purity
of the cell preparations was evaluated by flow cytometry and over
85% of CD11b
+/CD206
+ macrophages were consistently ob-
tained.
Chemerin binding assay
Chemerin binding assays were performed by incubating 2.10
5
mouse peritoneal macrophages, harvested after i.p. injection of
Bio-Gel polyacrylamide beads, in binding buffer (50 mM Hepes
pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 250 nM sucrose, 0.5% BSA)
with different concentrations of radioiodinated recombinant
human chemerin (R&D Systems, Abingdon, UK; custom labeling
performed by Perkin Elmer, Zaventem, Belgium). Non-specific
binding was measured in the presence of a 100-fold excess of
unlabeled chemerin. Samples were incubated for one hour and
unbound tracer was removed by filtration through GF/B filters
pre-soaked in 1% polyethyleneimine. Filters were counted in a c-
scintillation counter. Binding parameters of saturation curves were
determined with the PRISM software (Graphpad Softwares) using
non-linear regression applied to one site or two sites binding
models. The software compared the sum-of-square and the degree
of freedom of each regression by using the F test and selected the
most appropriate equation.
Aequorin-based calcium mobilization assay
Functional response of mouse ChemR23 to recombinant mouse
chemerin was determined by using an aequorin-based calcium
mobilization assay as previously described [13]. Briefly, CHO-K1
cells co-expressing mouse ChemR23, apoequorin and Ga16 (or
control CHO-K1 cells co-expressing apoaequorin and Ga16), were
incubated for 3 h in the dark in DMEM containing 5 mM
coelenterazine H (Invitrogen, Molecular Probes). 5.10
4 cells in
a volume of 50 ml were added to wells containing different
concentrations of recombinant mouse chemerin and luminescence
was recorded for 20 s in a Packard luminometer. Results (as
Chemerin Does Not Inhibit Inflammatory Responses
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ATP, and the parameters of the dose-response curves were
determined with the PRISM software using nonlinear regression
applied to a sigmoidal dose-response model.
Chemotaxis assay
Chemotaxis assays were performed on peritoneal macrophages
(Bio-Gel procedure) as previously described [7]. Briefly, migration
Figure 1. Effect of chemerin on the production of cytokines by activated mouse macrophages. Peritoneal macrophages from WT mice,
collected after i.p. thioglycolate injection, were exposed or not for 1 h to 100 nM recombinant mouse chemerin. The cells were further stimulated by
100 ng/ml LPS. Unstimulated cells were used as controls. (A) At the indicated time points, cells were harvested for the determination of transcript
levels for IL-6, TNF-a and IL-10, using quantitative RT-PCR. Results are expressed as mean 6 SEM for 2 independent experiments performed in
duplicate. (B) At the indicated time points, IL-6, TNF-a and IL-10 levels were determined in the supernatants by ELISA. Results are expressed as mean
6 SEM for 3 independent experiments performed in duplicate.
doi:10.1371/journal.pone.0040043.g001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e40043Figure 2. Mouse peritoneal macrophages express a functional ChemR23 receptor. (A) Peritoneal macrophages from WT or ChemR23
2/2
mice, collected following i.p. Bio-Gel injection, were stimulated for 15 h by 100 ng/ml LPS or left unstimulated. Cells were harvested, and expression
of ChemR23 was determined by quantitative RT-PCR. Data are expressed as mean 6 SEM for 3 independent experiments performed in duplicate. (B)
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microchemotaxis Boyden chamber with polycarbonate mem-
branes (5 mm pores, NeuroProbe, MD, USA). The cell suspension
(5.10
4 cells in 50 ml) was placed in the upper chamber. The lower
wells contained 30 ml of medium with different concentrations of
chemoattractant, and the chamber was incubated at 37uC for
90 min. All conditions were tested in triplicate. Controls were
performed in the absence of chemoattractant in the lower wells.
The results were expressed as migration ratio (mean cell number
per well with chemoattractant over mean cell number per well
without chemoattractant).
Macrophage activation assay
Murine macrophages obtained by the thioglycolate procedure
were preincubated for 1 h with 10
26 to 10
212 M recombinant
mouse (rm)-chemerin (R&D Systems) in RPMI 1640 medium
(Invitrogen), before challenging them with 100 ng/ml LPS (E. coli
strain 055:B5; Sigma-Aldrich, Bornem, Belgium). Murine macro-
phages obtained by the Bio-Gel procedure were preincubated for
1 h with 10
26 to 10
212 M rm-chemerin (R&D Systems) in Opti-
MEM I medium (Invitrogen), before challenging them with
100 ng/ml LPS (E. coli strain 055:B5; Sigma-Aldrich) and 20 ng/
ml rm-IFN-c (Peprotec). At selected time points after stimulation,
supernatants were harvested for cytokine determination and total
RNA was extracted from adherent cells for gene expression
analysis. Similarly, human macrophages were preincubated for
30 min with 10
28 M of recombinant human chemerin (R&D
Systems) and subsequently matured for 2, 4, 6, or 8 h by
incubation with 100 ng/ml LPS.
Cytokine assays
Supernatants of cultured macrophages were harvested and
levels of interleukin (IL)-1b (detection limit of 31.2 pg/ml), IL-6
(detection limit of 15.6 pg/ml), IL-10 (detection limit of 31.2 pg/
ml) and tumor necrosis factor (TNF)-a (detection limit of 15.6 pg/
ml) were determined by enzyme-linked immunosorbent assays (BD
Biosciences, Erembodegem, Belgium). In some experiments, total
RNA was extracted from cultured macrophages and purified using
the RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). After
DNase I treatment (Ambion), samples were reverse transcribed
into cDNA using random hexamers (Roche, Brussels, Belgium) as
primers and the Superscript III polymerase (Invitrogen). RT
products were analyzed by quantitative real-time RT-PCR. The
sequence of primer pairs used for mouse and human genes is
provided as supplemental data (Tab. S1 and S2). Raw data were
normalized for each sample using YWHAZ and CANX or
GAPDH transcripts as references.
Flow cytometry analysis
Peritoneal macrophages were incubated for 10 min at 4uC with
anti-CD16/CD32 monoclonal antibodies (BD Biosciences) to
block non-specific binding to Fc receptors. Then, cells were
stained with PE-conjugated anti-mouse CMKLR1 (e-Bioscience,
clone bz194, Vienna, Austria), FITC-conjugated anti-mouse F4-
80 (AbD Serotec, Dusseldorf, Germany), PerCp-conjugated anti-
mouse Gr1 (BD Biosciences) monoclonal antibodies or the
corresponding isotype-matched controls (BD Biosciences). All
samples were analyzed using a FC500 flow cytometer (Beckman-
Coulter).
Statistical analysis
Statistical analysis was performed using nonparametric t tests or
tests for multiple comparisons (Kruskal-Wallis test and the Dunn’s
multiple comparison post-test), using the GraphPad Prism 5
software. For all tests, a p value #0.05 was considered as
significant.
Results
Chemerin does not inhibit the LPS-induced production of
pro-inflammatory cytokines by thioglycolate-recruited
peritoneal macrophages
Previous experiments have shown that peritoneal macrophages
collected from WT mice following intraperitoneal injection of
thioglycolate express a functional ChemR23 receptor [7]. There-
fore, to further evaluate the potential anti-inflammatory effect of
chemerin reported by others [20], peritoneal macrophages were
recovered from WT and ChemR23
2/2 mice 4 days after
intraperitoneal injection of thioglycolate and tested in a time-
course experiment. Macrophages were stimulated by 100 ng/ml
LPS in the presence or absence of 100 nM rm-chemerin, and the
expression and release of cytokines were determined at different
time points respectively by quantitative RT-PCR (qRT-PCR) and
ELISA. As shown in Figure 1A, qRT-PCR analysis performed 2,
4, 6, 8, 12, 16 and 24 hours after LPS stimulation showed an
important time-dependent upregulation of TNF-a, IL-6 and IL-10
transcripts, with a peak observed at 4 to 6 hours for the three
cytokines. This LPS-induced upregulation was not affected by the
presence of 100 nM chemerin in the medium. At the protein level,
LPS-stimulated macrophages released high levels of TNF-a, IL-6
and IL-10 with, as expected, peak values obtained at later time-
points (i.e. 8–12 hours) than for the corresponding transcripts.
Similarly, no significant differences were observed in terms of
cytokine levels between cells treated or not with 100 nM of
chemerin (Figure 1B).
Peritoneal cells from WT or ChemR23
2/2 mice, collected following i.p. Bio-Gel injection, were analysed by flow cytometry, directly or after selection
by adherence to plates. Cells were stained for leukocyte markers (F4-80 and Gr1) and expression of ChemR23 on F4-80
+ Gr1
2 (Mw) and F4-80
2 Gr1
+
(PMN) cells was evaluated using flow cytometry. Histograms represent the fluorescence observed following ChemR23 staining on peritoneal cells
from WT (black histogram) or ChemR23
2/2 (white histogram) mice, compared to the isotype-matched control (dotted line). One representative
experiment out of 3 is shown. (C) Total peritoneal cells from WT and ChemR23
2/2 mice, collected following i.p. Bio-Gel injection, were incubated with
increasing concentrations of radiolabeled chemerin (N). Non-specific binding was determined in the presence of a 100-fold excess of unlabeled
chemerin (*), and specific binding (%) was calculated as the difference. One representative experiment out of 3 is shown. (D) Peritoneal macrophages
from WT or ChemR23
2/2 mice, collected following i.p. Bio-Gel injection, were tested for their ability to migrate in response to recombinant mouse
chemerin. In the left panel (mean 6 SEM for 3 independent experiments performed in quadruplicate), the whole populations of cells recovered was
used. In the right panel (mean 6 SD for an experiment performed in triplicate), macrophages selected by overnight adherence were used. Results are
expressed as migration index. (E) The biological activity of mouse recombinant chemerin was measured on mouse ChemR23-expressing CHO-K1 cells
using the aequorin-based intracellular Ca
2+ mobilization assay. Results are expressed as the percentage of the response to ATP and represent the
mean 6 SD of duplicated data points. One representative experiment out of 3 is shown.
doi:10.1371/journal.pone.0040043.g002
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polyacrylamide beads-treated mice express a functional
ChemR23 receptor
As we did not observe any anti-inflammatory activity of
chemerin on LPS-stimulated peritoneal macrophages collected
after thioglycolate injection, similar experiments were conducted
according to the protocol published by Cash et al. [20], using
macrophages collected after intraperitoneal injection of poly-
acrylamide beads and stimulated by LPS and IFN-c. Macrophages
(F4-80
+ Gr1
2 cells) represented about 45% of the total cells
harvested, and their purity was increased to over 90% following
selection by adherence to plates. The purity of the cell population
and the expression of ChemR23 were also evaluated after two
plating times (2 or 24 hours) without significant differences (data
not shown). The total number of cells and the percentage of F4-
80
+ Gr1
2 macrophages were not different between WT and
ChemR23
2/2 mice. To validate this protocol, we first confirmed
by qRT-PCR the presence of ChemR23 transcripts in the
macrophage population prepared from WT mice. We showed
also that stimulation by LPS did not significantly affect ChemR23
expression in these cells (Figure 2A). The same observation was
made following stimulation by IFN-c (data not shown). Using flow
cytometry, surface expression of ChemR23 was then evaluated on
cells collected by peritoneal lavage before and after plating. Using
a PE-conjugated anti-mouse ChemR23 mAb, we confirmed the
expression of the receptor on macrophages but not neutrophils
Figure 3. Dose-response effects of chemerin on the production of cytokines by activated peritoneal macrophages. Peritoneal
macrophages from WT (white bars) or ChemR23
2/2 (black bars) mice, collected following i.p. Bio-Gel injection and selected by adherence, were
tested for their production of pro-inflammatory (IL-6, IL-1b and TNF-a) and anti-inflammatory (IL-10) cytokines in response to stimulation by LPS and
IFN-c, in the presence or not of graded concentrations of recombinant chemerin (from 10
212 to 10
26 M). After 15 h of culture, supernatants were
collected and cytokine levels were determined by ELISA. Results are expressed as the percentage of the LPS/IFN-c-induced levels (left panels) or as
pg/ml (right panels) and represent the mean 6 SEM of 3 to 4 independent experiments.
doi:10.1371/journal.pone.0040043.g003
Figure 4. Production of cytokines by activated peritoneal macrophages. Peritoneal macrophages from WT (white bars) or ChemR23
2/2
(black bars) mice, collected following i.p. Bio-Gel injection and selected by adherence, were tested for their production of pro-inflammatory (IL-6, IL-
1b and TNF-a) and anti-inflammatory (IL-10) cytokines in response to stimulation by LPS and IFN-c, in the presence or not of graded concentrations of
recombinant chemerin (from 10
212 to 10
26 M) or 10
26 M dexamethasone (Dex). After 15 h of culture, supernatants were collected and cytokine
levels were determined by ELISA. The results, expressed as pg/ml, represent the mean 6 SD of 2 independent experiments.
doi:10.1371/journal.pone.0040043.g004
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2 Gr1
+ cells), using ChemR23
2/2 cells as controls
(Figure 2B). To further confirm the functional expression of
ChemR23 by macrophages, we performed binding studies using
radioiodinated chemerin and chemotaxis assays. In saturation
binding experiments, chemerin bound to cells at a single binding
site with a calculated Kd of about 1.2 nM (Figure 2C). This value
is similar to those obtained for chemerin binding on CHO-K1 cell
lines expressing recombinant mouse or human ChemR23 (1.1 nM
and 0.9 nM, respectively) (data not shown). In contrast, very weak
chemerin binding was detected on macrophages collected from
ChemR23
2/2 mice, confirming that ChemR23 is by far the main
chemerin receptor on these cells. Furthermore, macrophages
collected after intraperitoneal injection of polyacrylamide beads
and selected by adherence to plates, were also tested for their
capacity to migrate in response to chemerin. As expected, the cells
were shown to migrate in response to increasing concentrations of
chemerin with a typical bell-shaped curve culminating for
concentrations around 1 nM (Figure 2D); whereas cells collected
from ChemR23
2/2 mice failed to migrate over background levels
in response to chemerin. Taken together, these results demon-
strated that peritoneal macrophages collected 4 days after
intraperitoneal injection of polyacrylamide beads express a func-
tional ChemR23 receptor. Finally, we assessed whether rm-
chemerin used throughout our study was able to promote
intracellular calcium release through the ChemR23 receptor. A
CHO-K1 cell line expressing mouse ChemR23 was used in an
aequorin-based calcium release assay. We determined that rm-
chemerin wad indeed able to activate its receptor with an EC50 of
0.7 nM (Figure 2E). As a control, no calcium response was
observed in wild-type CHO-K1 cells exposed to rm-chemerin
(data not shown).
Chemerin does not inhibit cytokine production following
stimulation of mouse polyacrylamide-recruited
peritoneal macrophages or human blood-derived
macrophages
According to the macrophage activation assay described by
Cash et al. [20], peritoneal exudates obtained from polyacryl-
amide beads-treated WT and ChemR23
2/2 mice were allowed to
adhere for 2 hours. After extensive washing, cells were cultured in
OptiMEM medium, in the presence of a range of rm-chemerin
concentrations (from 10
212 to 10
26 M) for 1 hour and then
stimulated by LPS/IFN-c. After 15 h of culture, levels of TNF-a,
IL-1b, IL-6 and IL-10 in the supernatants were determined by
ELISA. As previously observed for thioglycolate-recruited perito-
neal macrophages stimulated by LPS alone, none of the induced
cytokines was significantly modulated by the presence of chemerin
at any concentration (Figure 3). As a control, peritoneal
macrophages were also treated with 1 mM dexamethasone before
stimulation by LPS/IFN-c. As shown in Figure 4, dexamethasone
repressed the production of pro-inflammatory cytokines, particu-
larly IL-6 and TNF-a. Finally, human macrophages differentiated
from peripheral blood monocytes were also generated to assess the
effect of chemerin on their LPS-induced cytokine production. As
illustrated in Figure 5, 100 nM of recombinant human chemerin
had no effect on the expression of the various cytokines tested.
Figure 5. Effects of chemerin on the production of cytokines by stimulated human macrophages. Human macrophages were obtained
as described in the Material and Methods section and were tested for their production of IL-6, TNF-a, IL-1b and IL-12p35 following stimulation by LPS,
in the absence or presence of 100 nM recombinant human chemerin. At various time points, cells were collected and cytokine transcript levels were
determined by quantitative RT-PCR. Results are expressed as fold increase over basal levels and represent the mean 6 SEM of 3 independent
experiments.
doi:10.1371/journal.pone.0040043.g005
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evaluated by qRT-PCR 2, 4, 6, and 8 hours after LPS stimulation,
were not significantly affected by the presence of chemerin in the
medium, whereas a strong increase was monitored in all cases,
with peak values obtained 2 (for TNF-a) or 4 hours (for IL-1b, IL-
10 and IL-12p35) after stimulation.
Discussion
In this study, we demonstrate that bioactive chemerin does not
exert any modulation of the cytokine inflammatory response of
mouse and human macrophages stimulated by LPS or LPS and
IFN-c, despite the large concentration range tested. Recently,
Cash and colleagues reported data suggesting that recombinant
chemerin at picomolar concentrations could behave in vitro as
a potent anti-inflammatory mediator on mouse peritoneal
macrophages stimulated by LPS and IFN-c, in a proteolysis-
dependent manner [20]. These in vitro observations were somehow
in line with our own in vivo results showing an anti-inflammatory
role of the chemerin/ChemR23 axis in a model of acute lung
injury induced by LPS [7] and a model of acute viral pneumonia
[8]. We therefore addressed the hypothesis of this putative direct
anti-inflammatory effect of chemerin on macrophage populations.
Surprisingly, while mouse peritoneal macrophages expressed a fully
functional ChemR23 and while recombinant chemerin induced
chemotaxis of peritoneal macrophages collected from WT but not
ChemR23
2/2 mice, we were not able to reproduce the in vitro
anti-inflammatory effects of chemerin. Our first experiments were
performed with macrophages recruited to the peritoneal cavity
using a different procedure than in Cash’s report and macro-
phages were stimulated in a medium containing fetal calf serum.
We therefore performed another set of experiments that were
conducted using experimental settings identical to those reported
by Cash and colleagues. Macrophages were obtained following
injection of polyacrylamide beads and stimulated in a serum-free
medium allowing the potential proteolysis of chemerin by
macrophage-derived proteases. However, even in these experi-
mental settings, no inhibition of the production of the pro-
inflammatory mediators TNF-a, IL-6 and IL-1b, and no
enhancement of the production of the anti-inflammatory cytokine
IL-10 were found when stimulated macrophages were exposed to
murine chemerin in a concentration range from 10
212 to 10
26 M.
We specifically used low picomolar concentrations of chemerin,
which are in our hands inactive even on cell lines expressing high
levels of recombinant human or mouse ChemR23, because Cash
and colleagues reported anti-inflammatory activities for such low
concentrations of chemerin. Indeed, such a high potency for
chemerin differs considerably from all previous experiments
showing that chemerin is active on ChemR23 in the 10
210 to
10
28 M range and peptides derived from its C-terminus in the
10
29 to 10
27 M range [4,13,14]. We confirmed in the present
study that low picomolar concentrations of recombinant chemerin
did not trigger any signalling in the sensitive aequorin-based
calcium mobilizing assay, which was characterized by a somewhat
classical EC50 of 0.7 nM. In addition, binding of
125I-chemerin on
peritoneal macrophages yielded a Kd value of about 1.2 nM.
Finally, no migration of peritoneal macrophages was observed for
low picomolar concentrations of chemerin. These results are in
agreement with other previous reports showing that mouse DCs
and lung interstitial macrophages express ChemR23 and exhibit
chemotactic responses to chemerin, but are not affected by
chemerin up to concentrations of 10
26 M in their production of
cytokines or expression of chemokine receptor following their
activation [7]. Discrepancies between our in vitro observations and
those of Cash and collaborators [20] might in part be explained by
the genetic background of the mice used in the respective studies.
Throughout our experiments, we used peritoneal macrophages
from WT and KO mice generated from the same line backcrossed
on the C57BL/6 background for over 10 generations (see Methods
section). Cash et al. used C57BL/6 mice for most experiments,
which should therefore be comparable, but also in some
experiments ChemR23 KO mice in the 129SvEv background.
In order to extend our observations to human cells, we also
evaluated the activity of recombinant human chemerin on human
macrophages differentiated from peripheral blood monocytes and
following stimulation by LPS. As for mouse cells, no anti-
inflammatory activities were identified for chemerin in this in vitro
setting.
As a conclusion, our results rule out a direct anti-inflammatory
effect of chemerin on macrophages. As a consequence, the anti-
inflammatory effects of the chemerin/ChemR23 system observed
in our models of viral pneumonia and LPS-induced acute lung
injury should be explained by other mechanisms. We presently
favor an hypothesis following which chemerin exerts its anti-
inflammatory properties through its activity on non-leukocytic
cells expressing ChemR23, such as epithelial or endothelial cells.
This hypothesis is supported by experiments performed on
chimeric mice showing that the anti-inflammatory activity of
chemerin is not mediated by bone marrow-derived leukocyte
populations [8], as well as data showing high expression of
ChemR23 in non-leukocytic lung cell populations [22].
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